BenjaminRixBrooksMD

Neurology • Charlotte, NC

Neuromuscular Medicine

Medical Director

Join to view full profile

Dr. Brooks is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brooks' full profile

Already have an account?

Office
1010 Edgehill Rd N
Charlotte, NC 28207
Phone+1 704-446-1900

Fax+1 704-466-6084

Education & Training

Johns Hopkins UniversityResidency, Neurology, 1976 - 1978
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1972 - 1974
Boston University Medical CenterResidency, Internal Medicine, 1970 - 1972
Harvard Medical SchoolClass of 1969

Certifications & Licensure

NC State Medical License 2008 - 2025
WI State Medical License 1982 - 2025
MD State Medical License 1976 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2020

Clinical Trials

Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS] Start of enrollment: 2001 Jan 01
Completed
Phase 2
Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2011 Mar 01
Completed
Phase 2
A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2011 Feb 01
Completed
Phase 2
Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2012 Jan 01
Completed
Not Applicable
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND) Start of enrollment: 2004 Mar 29
Terminated
Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2014 Sep 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Efficacy of Radicava® IV (intravenous edaravone) in subjects with differing trajectories of disease progression in amyotrophic lateral sclerosis: Use of a novel statis...
Erik P Pioro, Benjamin Rix Brooks, Ying Liu, Jeffrey Zhang, Stephen Apple
Journal of the Neurological Sciences. 2024-12-15
The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclero...
Benjamin Rix Brooks, Erik P Pioro, Takeshi Sakata, Fumihiro Takahashi, Melissa Hagan
Muscle & Nerve. 2023-10-01
3 citations
Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in Neurology.
Kathryn A Kvam, Michael Benatar, Alisa Brownlee, Tracie Caller, Rohit R Das
Neurology. 2023-08-01

Press Mentions

Mitsubishi Tanabe Pharma America Announces Real-World Data Analysis of Survival with RADICAVA® (Edaravone)August 15th, 2022
Mitsubishi Tanabe Pharma America Announces Long-Term Findings from Post-Marketing Safety Study of RADICAVA® (Edaravone)June 29th, 2022
#AAN2022 – US Real-World Data Show Radicava Boosts Survival RateApril 5th, 2022
Join now to see all

Grant Support

Tamoxifen Therapy On Mean Percent Predicted Isometric Strength In ALSNational Center For Research Resources2005
Phase II Study Of Hu23f2g In Acute Excerbations Of Multiple SclerosisNational Center For Research Resources1998–2002
Phase I Trial Of R-Methubdnf Given By Daily Injection To Patients With ALSNational Center For Research Resources1996
Phase I Safety And Tolerability Study Of BDNF In Patients With ALSNational Center For Research Resources1995–1996

Professional Memberships

American Academy of Neurology - AAN
Member